Experimental endoscopic endovascular cannulation: A novel approach to thrombolysis in retinal vessel occlusion

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 1, 2012, Pages 42-46

  Hattenbach, Lars Olof ^a   Puchta, Joachim ^b   Hilgenberg, Ingo ^c  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Hilgenberg GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; HYPERTONIC SOLUTION; SODIUM CHLORIDE;

ANIMAL TISSUE; ARTICLE; CADAVER; CANNULATION; CATHETER; CONTROLLED STUDY; ENDOSCOPIC ENDOVASCULAR CANNULATION; FIBRINOLYTIC THERAPY; NONHUMAN; PRIORITY JOURNAL; RELIABILITY; RETINA BLOOD VESSEL OCCLUSION; RETINA VEIN; SAFETY; SWINE; VEIN CATHETERIZATION;

ANIMALS; CATHETERIZATION; CATHETERIZATION, PERIPHERAL; DISEASE MODELS, ANIMAL; ENDOSCOPY; FIBRINOLYTIC AGENTS; INFUSIONS, INTRAVENOUS; RECOMBINANT PROTEINS; RETINAL VEIN; RETINAL VEIN OCCLUSION; SWINE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84855301442     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8486     Document Type: Article

References (34)

1. Quinlan PM, Elman MJ, Bhatt AK et al. The natural course of central retinal vein occlusion. Am J Ophthalmol. 1990;110:118-123.
2. Augsburger JJ, Magargal LE. Visual prognosis following treatment of acute central retinal artery obstruction. Br J Ophthalmol. 1980; 64:913-917.
3. Mandelcorn MS, Nrusimhadevara RK. Internal limiting membrane peeling for decompression of macular edema in retinal vein occlusion: a report of 14 cases. Retina. 2004;24:348-355.
4. Mason J 3rd, Feist R, White M. Jr, et al. Sheathotomy to decompress branch retinal vein occlusion: a matched control study. Ophthalmology. 2004;111:540-545.
5. Opremcak EM, Rehmar AJ, Ridenour CD, Kurz DE. Radial optic neurotomy for central retinal vein occlusion: 117 consecutive cases. Retina. 2006;26:297-305.
6. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146.
7. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117: 1102-1112.
8. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124-1133.
9. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009;50:1025-1032.
10. Sakurai K, Akiyama H, Shimoda Y, Yoshida I, Kurabayashi M, Kishi S. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes. Invest Ophthalmol Vis Sci. 2009;50:4905-4916.
11. Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Ophthalmol Vis Sci. 2008;49:4523-4527.
12. Kohner EM, Pettit JE, Hamilton AM. Streptokinase in central retinal vein occlusion: a controlled clinical trial. Br Med J. 1976;1:550-553.
13. Elman MJ. Thrombolytic therapy for central retinal vein occlusion: results of a pilot study. Trans Am Ophthalmol Soc. 1996;94:471-504.
14. Paques M, Vallee JM, Herbreteau D, et al. Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion. Br J Ophthalmol. 2000;84:1387-1391.
15. Hattenbach LO, Kuhli-Hattenbach C, Scharrer I, Baatz H. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion. Am J Ophthalmol. 2008;146:700-706.
16. Hattenbach LO, Arndt CF, Lerche R, et al. Retinal vein occlusion and low-dose fibrinolytic therapy (R.O.L.F.): a prospective, randomized, controlled multicenter study of low-dose recombinant tissue plasminogen activator versus hemodilution in retinal vein occlusion. Retina. 2009;29:932-940.
17. Richard G, Lerche RC, Knospe V, Zeumer H. Treatment of retinal arterial occlusion with local fibrinolysis using recombinant tissue plasminogen activator. Ophthalmology. 1999;106:768-773.
18. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
19. Sloan M, Gore JM. Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: a risk-benefit analysis. Am J Cardiol. 1992;69:21A-38A.
20. Glacet-Bernard A, Kuhn D, Vine AK et al. Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study. Br J Ophthalmol. 2000;84:609-613.
21. Weiss JN, Bynoe LA. Injection of tissue plasminogen activator into a branch retinal vein in eyes with central retinal vein occlusion. Ophthalmology. 2001;108:2249-2257.
22. Weiss JN. Treatment of central retinal vein occlusion by injection of tissue plasminogen activator into a retinal vein. Am J Ophthalmol. 1998;126:142-144.
23. Feltgen N, Junker B, Agostini H, Hansen LL. Retinal endovascular lysis in ischemic central retinal vein occlusion: one-year results of a pilot study. Ophthalmology. 2007;114:716-723.
24. Koch FH, Quiroz-Mercado H, Hattenbach LO, et al. Pigment epithelium endoscopic laser surgery for treatment of choroidal neovascularization. Ophthalmologica. 2004;218:162-175.
25. Faude F, Wiedemann P. Vitreoretinal endoscope for the assessment of the peripheral retina and the ciliary body after large retinectomies in severe anterior PVR. Int Ophthalmol. 2004;25: 53-56.
26. Tameesh MK, Lakhanpal RR, Fujii GY, et al. Retinal vein cannulation with prolonged infusion of tissue plasminogen activator (t-PA) for the treatment of experimental retinal vein occlusion in dogs. Am J Ophthalmol. 2004;138:829-839.
27. Jensen PS, Grace KW, Attariwala R, Colgate JE, Glucksberg MR. Toward robot-assisted vascular microsurgery in the retina. Graefes Arch Clin Exp Ophthalmol. 1997;235:696-701.
28. Glucksberg MR, Dunn R, Giebs CP. In vivo micropuncture of retinal vessels. Graefes Arch Clin Exp Ophthalmol. 1993;231:405-407.
29. Kadonosono K, Arakawa A, Yamane S, Uchio E, Yanagi Y. An experimental study of retinal endovascular surgery with a microfabricated needle. Invest Ophthalmol Vis Sci. 2011;52:5790-5793.
30. Tang WM, Han DP. A study of surgical approaches to retinal vascular occlusions. Arch Ophthalmol. 2000;118:138-143.
31. Suzuki J, Matsuhashi H, Nakazawa M. In vivo retinal vascular cannulation in rabbits. Graefes Arch Clin Exp Ophthalmol. 2003; 241:585-588.
32. Tsilimbaris MK, Lit ES, D'Amico DJ. Retinal microvascular surgery: a feasibility study. Invest Ophthalmol Vis Sci. 2004;45:1963-1968.
33. Schwenn OK, Wustenberg EG, Konerding MA, Hattenbach LO. Experimental percutaneous cannulation of the supraorbital arteries: implication for future therapy. Invest Ophthalmol Vis Sci. 2005;46:1557-1560.
34. Cho YP, Jang HJ, Lee DH, et al. Deep venous thrombosis associated with protein C and/or S deficiency: management with catheterdirected thrombolysis. Br J Radiol 2003;76:380-384.